Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer. Okines A, Turner N. Ann Oncol 2022 Mar 14. pii: S0923-7534(22)00364.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Okines A, Turner N. Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer. Ann Oncol 2022 Mar 14. pii: S0923-7534(22)00364.
PMID: 35301095